Menu
|
On June 19 and 20, the NOMAD partners gathered for our General Assembly at the laboratoire_mateis of INSA Lyon – Institut National des Sciences Appliquées de Lyon. Which key points were considered during this meeting?
📌 To maximise progress, new concepts has been developed for collaborative research and presented results on surface functionalisation (WP1) and controlled release strategies (WP2) in NOMAD biomaterials.
📌The methodology has been described for in vitro evaluation (WP4) and biomechanical stability testing (WP3) of the NOMAD biomaterials.
📌 External Advisory Board member Dr Yves Bayon, a specialist in the field of medical device invention and exploitation, and detailed discussion has been made about potential regulatory schemes for the NOMAD material advances.
📌 As one of the most important parameter; communication campaigns to engage NOMAD with many stakeholders and share the results of NOMAD (WP6).
📌Talking about our progress in a #teamwork environment full of enthusiasm was amazing. We are grateful to Laurent Gremillard from the CNRS/ECL team in Lyon for organising this hybrid event and look forward to our next meeting!Connect on LinkedIn!
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.
